Metastatic Solid Tumor Clinical Trials

123 clinical trials for Metastatic Solid Tumor across international registries, including 51 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — RECRUITING · PHASE1
• A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors — RECRUITING · PHASE1
• A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours — RECRUITING · PHASE1
• A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies — RECRUITING · PHASE1
• A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of IDP-001 in Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) — RECRUITING · PHASE2
• A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy — RECRUITING · PHASE1
• A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Combination Therapy in Cancers With Mutations in DNA Repair Genes — RECRUITING · PHASE1
• FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers — RECRUITING · PHASE1
• First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors — RECRUITING · PHASE1
• Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer — RECRUITING · PHASE1
• A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer — RECRUITING · PHASE1
• Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — RECRUITING · PHASE1
• GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors — RECRUITING · PHASE1
• Pemigatinib + Afatinib in Advanced Refractory Solid Tumors — RECRUITING · PHASE1
• Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) — RECRUITING · PHASE1
• A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue — RECRUITING · NA
• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors — RECRUITING · PHASE1
• Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) — RECRUITING · PHASE1
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation — RECRUITING · PHASE1
• Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors — RECRUITING · PHASE2
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of KK2269 in Adult Participants With Solid Tumors — RECRUITING · PHASE1
• Safety and Early Signs of Efficacy of IL12-L19L19. — RECRUITING · PHASE1
• Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 — RECRUITING · PHASE1
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors — RECRUITING · PHASE1
• JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) — RECRUITING · PHASE1
• A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies — RECRUITING · PHASE1
• A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab — RECRUITING · PHASE1
• Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) — RECRUITING · PHASE1
• A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer — RECRUITING · PHASE1
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) — RECRUITING · PHASE1
• A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• High Definition Medicine for Solid Tumors Oncology — RECRUITING

Refine this search